TY - JOUR
T1 - New classification and diagnostic criteria for insulin resistance syndrome
AU - Ogawa, Wataru
AU - Araki, Eiichi
AU - Ishigaki, Yasushi
AU - Hirota, Yushi
AU - Maegawa, Hiroshi
AU - Yamauchi, Toshimasa
AU - Yorifuji, Tohru
AU - Katagiri, Hideki
N1 - Funding Information:
Wataru Ogawa: Lecture fee (Sumitomo Dainippon Pharma Co., Ltd., Novartis Pharma K.K., Nippon Boehringer Ingelheim Co., Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Abbott Japan), Total amount of research expenses (joint research, commissioned research, clinical trials, etc.) and grants (Noster, Nippon Boehringer Ingelheim Co., Ltd., Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly Japan K.K., Novo Nordisk Pharma LTD., Abbott Japan, Abbott Diabetes Care UK Ltd, Sumitomo Dainippon Pharma Co., Ltd.), Total amount of scholarships (incentives) (Kowa Company, Ltd., Novo Nordisk Pharma LTD., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., ONO PHARMACEUTICAL CO., LTD., Takeda Pharmaceutical Co. Ltd., Abbott Japan, Novartis Pharma K.K., DAIICHI SANKYO CO., LTD., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co ., Ltd.), Eiichi Araki: Lecture fees (AstraZeneca, MSD, ONO PHARMACEUTICAL CO., LTD., Kowa Company, Ltd., Sanofi, DAIICHI SANKYO CO., LTD., Sumitomo Dainippon Pharma Co., Ltd., Novo Nordisk Pharma LTD.), Total amount of scholarships (incentives) (Astellas Pharma Inc., Kowa Company, Ltd., Sanofi, DAIICHI SANKYO CO., LTD., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Novo Nordisk Pharma LTD. Bayer Yakuhin Ltd), Endowed chair (ONO PHARMACEUTICAL CO., LTD., Terumo Corporation), Yasushi Ishigaki: Lecture fees (MSD, Novartis Pharma K.K., Mitsubishi Tanabe Pharma Corporation, Sanofi, ONO PHARMACEUTICAL CO., LTD., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Novo Nordisk Pharma LTD.), Total amount of research expenses (joint research, commissioned research, clinical trials, etc.) and grants (Novo Nordisk Pharma LTD., DAIICHI SANKYO CO., LTD.), Total amount of scholarships (incentives) donations (Novartis Pharma K.K., ONO PHARMACEUTICAL CO., LTD., Takeda Science Foundation), Yushi Hirota: Lecture fee (Eli Lilly Japan K.K. Sanofi), Hiroshi Maegawa: Lecture fees (Sanofi, Nippon Boehringer Ingelheim Co., Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma LTD., Sumitomo Dainippon Pharma Co., Ltd., MSD, Astellas Pharma Inc., DAIICHI SANKYO CO., LTD., AstraZeneca, Eli Lilly Japan K.K.), Total amount of research fees (joint research, commissioned research, clinical trials, etc.) and grants (Nippon Boehringer Ingelheim Co., Ltd., Sunstar, Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co., Ltd. And Cimic Co., Ltd., Nissan Chemical Corporation, MIKI Corporation, Parexel), Total amount of scholarships (incentives) (Takeda Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim Co., Ltd., Mitsubishi Tanabe Pharma Corporation, DAIICHI SANKYO CO., LTD., Sumitomo Dainippon Pharma Co., Ltd., Kowa Company, Ltd., Sanwa Kagakukenkyusho Co, Ltd., Novo Nordisk Pharma LTD., Nipro Corporation, Astellas Pharma Inc., MSD, Taisho Pharma Co., Ltd., ONO PHARMACEUTICAL CO., LTD., Bayer Yakuhin Ltd, Novartis Pharma K.K.), Toshimasa Yamauchi: Lecture fees (Astellas Pharma Inc., AstraZeneca, ONO PHARMACEUTICAL CO., LTD., Sanofi, Takeda Pharmaceutical Co. Ltd., DAIICHI SANKYO CO., LTD., Novartis Pharma K.K., Novo Nordisk Pharma LTD.), Total amount of research expenses (joint research, commission research, clinical trials, etc.) and grants (Astra Zeneca, Kowa Company, Ltd., MSD, DAIICHI SANKYO CO., LTD., Sanofi, Nippon Boehringer Ingelheim Co., Ltd., Aero Switch Therapeutics, Inc., Sanwa Kagakukenkyusho Co, Ltd., Minophagen Pharmaceutical Co., LTD., Mitsubishi Corporation Life Sciences Limited, Nipro Corporation), Total amount of scholarships (incentives) (Kissei Pharmaceutical Co., Ltd., Taisho Pharma Co., Ltd., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Sanofi, Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., Novo Nordisk Pharma LTD., ONO PHARMACEUTICAL CO., LTD., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co. Ltd., Sanwa Kagakukenkyosho Co, Ltd.), Endowed chair offered by companies, etc. (Takeda Pharmaceutical Co. Ltd., ONO PHARMACEUTICAL CO., LTD., Novo Nordisk Pharma LTD., Mitsubishi Tanabe Pharma Corporation, MSD, Nippon Boehringer Ingelheim Co., Ltd., Kowa Company, Ltd., NTT Docomo Inc., Asahi Mutual Life Insurance Co), Tohru Yorifuji: Lecture fees (Novo Nordisk Pharma LTD.), Hideki Katagiri: Lecture fees (Mitsubishi Tanabe Pharma Corporation, Sanofi, Novo Nordisk Pharma LTD.), Total amount of research expenses (joint research, commission research, clinical trials, etc.) and grants (Otsuka Pharmaceutical Co., Ltd., Suntory Holdings Limited, Astellas Pharma Inc.), Total amount of scholarships (incentives) donations (Takeda Pharmaceutical Co. Ltd., DAIICHI SANKYO CO., LTD., Novartis Pharma K.K., Mitsubishi Tanabe Pharma Corporation, ONO PHARMACEUTICAL CO., LTD., Eli Lilly Japan K.K., MSD., Sanofi., Novo Nordisk Pharma LTD.)
Publisher Copyright:
© 2022, Japan Endocrine Society. All rights reserved.
PY - 2022
Y1 - 2022
N2 - This report of a working group established by the Japan Diabetes Society proposes a new classification and diagnostic criteria for insulin resistance syndrome. Insulin resistance syndrome is defined as a condition characterized by severe attenuation of insulin action due to functional impairment of the insulin receptor or its downstream signaling molecules. This syndrome is classified into two types: genetic insulin resistance syndrome, caused by gene abnormalities, and type B insulin resistance syndrome, caused by autoantibodies to the insulin receptor. Genetic insulin resistance syndrome includes type A insulin resistance as well as Donohue and Rabson-Mendenhall syndromes, all of which are caused by abnormalities of the insulin receptor gene; conditions such as SHORT syndrome caused by abnormalities of PIK3R1, which encodes a regulatory subunit of phosphatidylinositol 3-kinase; conditions caused by abnormalities of AKT2, TBC1D4, or PRKCE; and conditions in which a causative gene has not yet been identified. Type B insulin resistance syndrome is characterized by severe impairment of insulin action due to the presence of insulin receptor autoantibodies. Cases in which hypoglycemia alone is induced by autoantibodies that stimulate insulin receptor were not included in Type B insulin resistance syndrome.
AB - This report of a working group established by the Japan Diabetes Society proposes a new classification and diagnostic criteria for insulin resistance syndrome. Insulin resistance syndrome is defined as a condition characterized by severe attenuation of insulin action due to functional impairment of the insulin receptor or its downstream signaling molecules. This syndrome is classified into two types: genetic insulin resistance syndrome, caused by gene abnormalities, and type B insulin resistance syndrome, caused by autoantibodies to the insulin receptor. Genetic insulin resistance syndrome includes type A insulin resistance as well as Donohue and Rabson-Mendenhall syndromes, all of which are caused by abnormalities of the insulin receptor gene; conditions such as SHORT syndrome caused by abnormalities of PIK3R1, which encodes a regulatory subunit of phosphatidylinositol 3-kinase; conditions caused by abnormalities of AKT2, TBC1D4, or PRKCE; and conditions in which a causative gene has not yet been identified. Type B insulin resistance syndrome is characterized by severe impairment of insulin action due to the presence of insulin receptor autoantibodies. Cases in which hypoglycemia alone is induced by autoantibodies that stimulate insulin receptor were not included in Type B insulin resistance syndrome.
KW - Insulin receptor
KW - Insulin receptor autoantibodies
KW - Type A insulin resistance syndrome
KW - Type B insulin resistance syndrome
UR - http://www.scopus.com/inward/record.url?scp=85125554287&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125554287&partnerID=8YFLogxK
U2 - 10.1507/endocrj.EJ21-0725
DO - 10.1507/endocrj.EJ21-0725
M3 - Article
C2 - 35110500
AN - SCOPUS:85125554287
SN - 0918-8959
VL - 69
SP - 107
EP - 113
JO - Endocrine Journal
JF - Endocrine Journal
IS - 2
ER -